BioMed research international · 2026
Urinary Epithelial Cell Adhesion Molecule (EpCAM) as a Noninvasive Biomarker for Detecting Clinically Significant Prostate Cancer in Men With Equivocal PSA Levels.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Opoku Mensah Bismark, Fondjo Linda Ahenkorah, Nsiah Paul, Edwards Emma
Аннотация
BACKGROUND: Prostate-specific antigen (PSA) is widely used for prostate cancer screening, but its limited specificity in the diagnostic "grey zone" (4-10 ng/mL) results in unnecessary biopsies. This study evaluated urinary epithelial cell adhesion molecule (EpCAM), normalised to urinary creatinine, as a noninvasive biomarker for identifying clinically significant prostate cancer (csPCa) in men with equivocal PSA levels.
METHODS: This cross-sectional study included 286 men with PSA levels of 4-10 ng/mL scheduled for prostate biopsy. Histopathological outcomes were classified using ISUP Grade Groups. Urinary EpCAM was quantified by ELISA, and diagnostic performance for csPCa was assessed using nonparametric analyses, ROC curves and logistic regression.
RESULTS: Urinary EpCAM/Cr levels increased significantly across diagnostic categories and were highest in men with csPCa (p < 0.001). EpCAM/Cr showed strong discrimination for csPCa (AUC = 0.816), outperforming serum PSA and PSA density. In multivariable analysis, EpCAM/Cr (aOR = 1.07; 95% CI: 1.02-1.14; p = 0.009) and PSA density (aOR = 1.81; 95% CI: 1.20-3.18; p = 0.013) were independent predictors of csPCa, and EpCAM/Cr correlated positively with tumour aggressiveness (ρ = 0.609; p < 0.001).
CONCLUSION: Urinary EpCAM/Cr shows promise as a noninvasive biomarker for detecting csPCa in men with PSA levels in the diagnostic grey zone.
METHODS: This cross-sectional study included 286 men with PSA levels of 4-10 ng/mL scheduled for prostate biopsy. Histopathological outcomes were classified using ISUP Grade Groups. Urinary EpCAM was quantified by ELISA, and diagnostic performance for csPCa was assessed using nonparametric analyses, ROC curves and logistic regression.
RESULTS: Urinary EpCAM/Cr levels increased significantly across diagnostic categories and were highest in men with csPCa (p < 0.001). EpCAM/Cr showed strong discrimination for csPCa (AUC = 0.816), outperforming serum PSA and PSA density. In multivariable analysis, EpCAM/Cr (aOR = 1.07; 95% CI: 1.02-1.14; p = 0.009) and PSA density (aOR = 1.81; 95% CI: 1.20-3.18; p = 0.013) were independent predictors of csPCa, and EpCAM/Cr correlated positively with tumour aggressiveness (ρ = 0.609; p < 0.001).
CONCLUSION: Urinary EpCAM/Cr shows promise as a noninvasive biomarker for detecting csPCa in men with PSA levels in the diagnostic grey zone.